Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 17/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.46 |
| ▸ | IKZF2 | Q9UKS7 | 3/20 | 0.40 |
| ▸ | WIZ | O95785 | 1/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.38 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5213729 | 0.83 | CRBN (0.50) | CRBNDDB1IKZF3 | |
| SCHEMBL5215670 | 0.83 | CRBN (0.44) | PDE3BPDE3ACRBNDDB1IKZF3 | |
| SCHEMBL5215745 | 0.81 | CRBN (0.50) | CRBNDDB1IKZF3 | |
| SCHEMBL5162159 | 0.80 | CRBN (0.58) | CRBNDDB1IKZF3 | |
| SCHEMBL1398098 | 0.80 | HPGDS (0.41) | PDE3BPDE3ACRBNDDB1 | |
| SCHEMBL5217927 | 0.78 | CRBN (0.43) | CRBNDDB1IKZF3 | |
| SCHEMBL5217370 | 0.76 | CRBN (0.56) | CRBNDDB1IKZF3 | |
| SCHEMBL5215782 | 0.76 | CRBN (0.44) | CRBNDDB1IKZF3 | |
| SCHEMBL5216879 | 0.76 | CRBN (0.50) | CRBNDDB1IKZF3 | |
| SCHEMBL5217842 | 0.76 | CRBN (0.47) | CRBNDDB1IKZF2CSNK1A1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1456197-B1 | PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 | GRUENENTHAL GMBH (DE) | 2007-02-28 | — | — | EP | claimed |
| US-7183274-B2 | Piperidine-2,6-diones heterocyclically substituted in the 3-position | GRUENENTHAL GMBH (DE) | 2007-02-27 | — | — | US | claimed |
| US-20050020581-A1 | Piperidine-2,6-diones heterocyclically substituted in the 3-position | GRUENENTHAL GMBH (DE) | 2005-01-27 | — | — | US | claimed |
| EP-1456197-A1 | PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 | Grünenthal GmbH (DE) | 2004-09-15 | — | — | EP | claimed |
| WO-2003053956-A1 | PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 | Grünenthal GmbH (DE) | 2003-07-03 | — | — | WO | claimed |
| EP-1456197-B1 | PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 | GRUENENTHAL GMBH (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-7183274-B2 | Piperidine-2,6-diones heterocyclically substituted in the 3-position | GRUENENTHAL GMBH (DE) | 2007-02-27 | — | — | US | disclosed |
| US-20050020581-A1 | Piperidine-2,6-diones heterocyclically substituted in the 3-position | GRUENENTHAL GMBH (DE) | 2005-01-27 | — | — | US | disclosed |
| EP-1456197-A1 | PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 | Grünenthal GmbH (DE) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003053956-A1 | PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 | Grünenthal GmbH (DE) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020581-A1 | Piperidine-2,6-diones heterocyclically substituted in the 3-position | DPYD, CYP2D6, DHPS | PDE3B 48/4885PDE3A 32/4885CRBN 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.